These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34087050)

  • 1. Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan).
    Eadie AL; Brunt KR; Herder M
    Pharmacol Res Perspect; 2021 May; 9(3):e00794. PubMed ID: 34087050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions.
    Galo J; Celli D; Colombo R
    Am J Cardiovasc Drugs; 2021 May; 21(3):267-270. PubMed ID: 33063249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US.
    Vaduganathan M; Claggett BL; Greene SJ; Aggarwal R; Bhatt AS; McMurray JJV; Fonarow GC; Solomon SD
    JAMA Cardiol; 2021 Dec; 6(12):1415-1423. PubMed ID: 34524394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.
    Gandotra C; Clark J; Liu Q; Senatore FF; Rose M; Zhang J; Stockbridge NL
    Ther Innov Regul Sci; 2022 Jan; 56(1):4-7. PubMed ID: 34699047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
    Tsutsui H; Momomura S; Saito Y; Ito H; Yamamoto K; Ohishi T; Okino N; Guo W
    J Cardiol; 2017 Sep; 70(3):225-231. PubMed ID: 28024961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap.
    Perez AL; Kittipibul V; Tang WHW; Starling RC
    JACC Heart Fail; 2017 Jun; 5(6):460-463. PubMed ID: 28571599
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Recommendation for Angiotensin Receptor-Neprilysin Inhibitor: First Medication Approval for Heart Failure Without Reduced Ejection Fraction.
    Howlett JG
    Can J Cardiol; 2021 Apr; 37(4):528-530. PubMed ID: 33484837
    [No Abstract]   [Full Text] [Related]  

  • 13. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/valsartan (Entresto) utilisation and prescribing patterns in the context of a reimbursement application system.
    Kennedy C; Smith A; Doran S; Barry M
    Br J Clin Pharmacol; 2021 Feb; 87(2):406-413. PubMed ID: 32470158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.
    Kapelios CJ; Lainscak M; Savarese G; Laroche C; Seferovic P; Ruschitzka F; Coats A; Anker SD; Crespo-Leiro MG; Filippatos G; Piepoli MF; Rosano G; Zanolla L; Aguiar C; Murin J; Leszek P; McDonagh T; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2019 Nov; 21(11):1383-1397. PubMed ID: 31132222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    Abumayyaleh M; El-Battrawy I; Behnes M; Borggrefe M; Akin I
    Future Cardiol; 2020 Jul; 16(4):227-236. PubMed ID: 32186406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.
    Zhang R; Sun X; Li Y; He W; Zhu H; Liu B; Zhang A
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484211058681. PubMed ID: 34994233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
    McMurray JJV; Jackson AM; Lam CSP; Redfield MM; Anand IS; Ge J; Lefkowitz MP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Rizkala AR; Sabarwal SV; Shah AM; Shah SJ; Shi VC; van Veldhuisen DJ; Zannad F; Zile MR; Cikes M; Goncalvesova E; Katova T; Kosztin A; Lelonek M; Sweitzer N; Vardeny O; Claggett B; Jhund PS; Solomon SD
    Circulation; 2020 Feb; 141(5):338-351. PubMed ID: 31736337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entresto, a New Panacea for Heart Failure?
    Khalil P; Kabbach G; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2018; 16(1):5-11. PubMed ID: 29532764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.